Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · IEX Real-Time Price · USD
24.46
-0.03 (-0.12%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Mirum Pharmaceuticals Revenue
In the year 2023, Mirum Pharmaceuticals had annual revenue of $186.37M with 141.85% growth. Revenue in the quarter ending December 31, 2023 was $69.55M with 149.24% year-over-year growth.
Revenue (ttm)
$186.37M
Revenue Growth
+141.85%
P/S Ratio
6.18
Revenue / Employee
$705,962
Employees
264
Market Cap
1.15B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 186.37M | 109.31M | 141.85% |
| Dec 31, 2022 | 77.06M | 57.92M | 302.66% |
| Dec 31, 2021 | 19.14M | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Collegium Pharmaceutical | 566.77M |
| AtriCure | 399.25M |
| Phreesia | 356.30M |
| MannKind | 198.96M |
| Prothena Corporation | 91.37M |
| Vir Biotechnology | 86.18M |
| AbCellera Biologics | 38.03M |
MIRM News
- 17 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 26 days ago - Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome - Business Wire
- 6 weeks ago - US FDA approves expanded use of Mirum's liver disease drug - Reuters
- 6 weeks ago - Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis - Business Wire
- 7 weeks ago - Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024 - Business Wire
- 3 months ago - Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer - Business Wire